Exelixis, Inc. called it quits on trying to bring multi-kinase inhibitor Cabometyx into first-line hepatocellular carcinoma (HCC), after the Phase III COSMIC-312 combination trial failed to yield an overall survival benefit in previously untreated HCC. The company said the survival readout showed “neither improvement nor detriment” and indicated that it would not go ahead with a planned supplemental filing, also citing the “rapidly evolving treatment landscape” as further rationale for the decision.
The 14 March announcement included no numerical data for overall survival (OS) or any other endpoints in the 837-patient, three-arm trial, which tested Cabometyx (cabozantinib) as monotherapy and in combination with Roche Holding AG’s PD-L1 inhibitor Tecentriq (atezolizumab) against Bayer AG’s Nexavar (sorafenib)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?